Lilly, AZ, AbbVie and J&J are among the drugmakers who stand to lose the most product revenue from proposed legislation that would allow Medicare to negotiate prices.
Teva to settle opioid claims for $4.25B — but with no admission of wrongdoing
An appeals court’s rejection of Pfizer’s bid to directly defray Medicare patients’ out-of-pocket drug costs could have a deterrent effect on the use of copay programs.
Moves to protect abortion, contraception access may fall short